Increase Speed to Market: Utilizing Enhanced ATP Bioluminescence for Rapid Microbial Detection - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Increase Speed to Market: Utilizing Enhanced ATP Bioluminescence for Rapid Microbial Detection
A new adenosine triphosphate bioluminesence technology allows manufacturers to detect the presence of microbial contamination within 24–48 hours rather than the 3–5 days required by traditional methods.

Pharmaceutical Technology

Study 2: Microbial Detection Optimization

Part 1: Six different fabric softeners were tested using standard and AKuScreen reagents. The fabric softeners were spiked (<10 cells) with three yeast species and five Acetobacter species and enriched in SDB. The product-broth suspensions were tested after 24, 48, 65 and 72 hours.

Table III: Case Study 2, Study II, Methodology
All three yeasts (Saccharomyces sp., Candida albicans, and C. guillermondii) were detected within 24 hours with both standard and AKuScreen bioluminescence reagents. The following table is data for the five Acetobacter species. (See Table III)

Table IV: Case Study 2, Study II, Detection Using AkuScreen Assay
Part 2: Five different naturally contaminated fabric softeners were tested using AKuScreen to determine the minimum incubation time required to detect microbial contamination directly from naturally contaminated products. Each product was tested in triplicate. The number of colony-forming-units (CFUs) per gram was determined at the same time the samples were set-up for Celsis enrichment. The product-broth suspensions were tested after 24, 48, and 72 hours.(See Table IV)

AKuScreen could detect Acetobacter species contamination within 48 hours. One of the replicates for the product with the lowest bioburden was negative at 48 hours but could be detected at 72 hours.

Results: The data shows that product-adapted microorganisms can be detected faster using AKuScreen. Detection was optimized by using a suitable enrichment broth. The detection system's ability to detect low numbers of product-adapted microorganisms is due to the amplification of ATP using adenylate kinase technology in the AkuScreen reagents. The company was able to manufacture and ship its fabric softener in a timely manner without having to worry about the downstream impact of a contamination event identified after products had shipped.

Broad Application for Rapid Methods

The economic benefits of implementing rapid microbial detection methods are clearly recognized by pharmaceutical manufacturers globally. The ability to release product faster is critical to effectively reducing manufacturing cycle times, reducing inventory holding time, and thereby increasing available working capital.

On the technology side, ATP bioluminescence is broadly utilized and accepted for rapid screening on a wide range of materials and finished goods. The use of AK can further shorten the detection cycle and improve key manufacturing metrics for many companies. AK is especially important to consider in certain product applications where the use of standard bioluminescence has its limitations. If a product has a high level of ATP from non-microbial sources, or if the product is contaminated with slow-growing organisms, for example, definitive detection can be more difficult to achieve with standard ATP.

In these selected situations, as illustrated by the above case studies, Celsis AKuScreen offers definitive detection while, at the same time, further decreasing time to result. Detection time decreases from 3-5 days with traditional detection methods to 24-48 hours with standard ATP Bioluminescence to 18-24 hours with AkuScreen.

Lori Daane is vice-president of Scientific Affairs, Celsis, Inc., 600 West Chicago Avenue, Suite 625, Chicago, IL 60610-2422. tel. 312.476.1200, fax 312.476.1201,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here